Skip to main content
Download PDF

Growth and endocrinopathies among children with β-Thalassemia major treated at Dubai Thalassemia centre

BMC Pediatrics volume 24, Article number: 244 (2024) Cite this article

Abstract

Background

β-Thalassemia major (BTM) is one of the most common hereditary anemias worldwide. Patients suffer from iron overload that results from repeated blood transfusion This in turn leads to multiple organ damage and endocrinopathies. This study aims to assess the prevalence of growth retardation, hypothyroidism, and diabetes mellitus in children and adolescents with BTM treated at Dubai Thalassemia Centre.

Methods

A total of 105 children and adolescents were included in this retrospective observational study.

Results

39 children and 66 adolescents’ data were analyzed. Females composed 51.3% (n = 20) of children and 53.0% (n = 35) of adolescents. Pretransfusion hemoglobin below 9 gm/dl was observed in 10.8% (n = 4) and 10.6% (n = 7) in children and adolescents, respectively. The mean age of menarche was 13.5 years. Among all study participants, 22.6% (n = 14) had normal height velocity whereas 37.1% (n = 23) had reduced height velocity in one year and 40.3% (n = 25) had reduced height velocity in two consecutive years. The proportion of children and adolescents showing reduced height velocity was significantly higher in females compared to the males (90.6% versus 63.3%, respectively, Chi-square = 6.597, p-value = 0.010). Although none of the study participants had diabetes mellitus, 26.1% (n = 12/46) had pre-diabetes. Elevated TSH was observed in 14.7% (n = 5) children and 8.1% (n = 5) adolescents while low FT4 was reported in one child and one adolescent.

Conclusion

Of all endocrinopathies seen among children and adolescents with BTM, growth delay remains the main concern for this group of patients. Effective treatment is key to further reducing endocrinopathies. Although the sample size is limited, we postulate that the low percentage of endocrinopathies among children with BTM treated at Dubai thalassemia center and the low level of pretransfusion anemia reflect the effective transfusion and chelation at the center.

Peer Review reports

Introduction

β-Thalassemia major (BTM) is a heterogenous group of hemolytic anemias that have an autosomal recessive inheritance. Anemia can result from reduced synthesis (β+) or complete absence (β0) of production of the β-globin’s hemoglobin chain [1, 2]. The complications of iron overload, arising from transfusions that represent the basis of disease management in most patients with severe thalassemia, might further complicate the clinical phenotype. Patients with BTM receive blood transfusion on regular basis loading the body with iron at a rate of 0.3-0.6 mg/kg/day and with the fact that the human body has poor mechanism of eliminating iron from the body [3]. The excess iron is deposited in different organs predominantly in the heart, liver, and endocrine glands giving rise to medical complications from iron toxicity, oxidative stress, and cell death [4]. The cardiac complications, such as left ventricular systolic and diastolic dysfunction, pulmonary hypertension, valvulopathies, arrhythmias and pericarditis, are the leading cause of death in patients with BTM [5]. Iron overload can disrupt the normal coaptation of the valve leaflets, resulting in incomplete closure and regurgitation of blood. Valvar regurgitation can lead to volume overload of the affected chambers of the heart, potentially causing further complications and impairing cardiac function [6]. Also, the liver is affected as iron overload can lead to liver failure and cirrhosis [7].

The endocrine system seems particularly sensitive to iron deposition. Data suggest that severe pituitary iron deposition occurs as early as the first decade in life and then leads to multiple endocrine complications at the level of hypothalamic- pituitary level [8]. Direct damage in the endocrine glands namely the thyroid, parathyroid, pancreas, and gonads occurs as well. Firstly, the thyroid gland is susceptible to cell death from the effect of free unbound iron particles, in addition to the effect of hypoxia from chronic anemia [9]. Secondly, the parathyroid gland, like any other gland, seems to be affected by toxic iron leading to subclinical hypoparathyroidism and less commonly to overt or symptomatic hypoparathyroidism with symptoms of hypocalcemia i.e. seizure and tetany [10]. Thirdly, data suggest that the pancreas is no exception to the toxic effect of iron. Studies have shown that adolescents treated with regular blood transfusion show evidence of insulin resistance and higher insulin secretion compared with non-thalassemia controls before the development of diabetes [11]. Furthermore, children and adolescents with poor or no chelation therapy showed more evidence of insulin resistance than their counterparts on iron chelation therapy [12]. Growth failure and hypogonadism are regarded among the commonest endocrinopathies in surviving thalassemia patients mainly due to hemosiderosis [13].

Dubai Thalassemia Centre is located in Dubai; one of seven Emirates constituting the United Arab Emirates; and except for the Emirate of Abu Dhabi, the Centre serves patients from all the other Emirates.

This study aims to assess the prevalence of endocrinopathies namely diabetes mellitus, hypothyroidism, growth delay, and delayed puberty among children and adolescents treated at Dubai Thalassemia Centre.

Materials and methods

Study design

This study has an observational retrospective cohort research design. Retrospective data, of all patients with BTM aged above two years and attended the Dubai Thalassemia Centre during the period of November 2019 and May 2021, were extracted from patients’ electronic medical records.

Collection of data

In this retrospective study, data were extracted from the medical records as related to patients’ sociodemographic and clinical characteristics. Two separate data collection sheets were used to extract data from the records of male and female patients. For both genders, sociodemographic and physiological characteristics including date of birth, gender, nationality, patient’s weight and height were collected. The daily intake of dairy products, supplements and drug compliance were also collected. Data related to the secondary sex characteristics of females and males were recorded. Extracted clinical data included full blood count, thyroid profile, bone health, and liver function tests. The diagnosis of BTM was initially done based on the clinical presentation and was then confirmed by DNA analysis and hemoglobin electrophoresis.

Data analysis

Data were initially entered on Microsoft Excel and were then exported to Statistical Package for Social Sciences (SPSS) program, version 28.0, for data coding and analysis. Descriptive data analysis was conducted using frequency distribution statistics (counts and percentages) for qualitative variables and measures of central tendency (means and medians) and variability (standard deviation and interquartile range) for quantitative data. Statistical tests were conducted as appropriate to the type of analyzed data. Means and standard deviations (SD) were reported for normally distributed data while medians and interquartile range (Q1-Q3) were reported for skewed data. To test the normality of quantitative data, Kolmogorov-Smirnov and Shapiro-Wilk tests were used while testing the equality of variances was performed using the Levene’s test. The independent t-test or Mann-Whitney U test were used to test the equality of two means or medians, respectively. One-way analysis of variance (ANOVA) or Kruskal-Wallis tests were used to test the equality of more than two means or medians, respectively. Missing data was handled using the pairwise deletion approach. A p-value below 0.05 indicated statistical significance.

Based on age, the cohort was classified as children (2–9 years) and adolescents(10–18 years). To measure the prevalence of diabetes mellitus, fasting blood glucose (FBG) level was categorized into three groups: normal (FBG < 100 mg/dL), prediabetes (FBG 100 mg/dL − 125 mg/dL) and diabetes (FBG ≥ 126 mg/dL) [14, 15]. Blood transfusion was performed to maintain the pretransfusion hemoglobin level above 9 g/dL as per thalassemia transfusion guidelines [16,17,18]. Thyroid-Stimulating Hormone (TSH) was dichotomized into two groups: normal (TSH between 0.3 and 4.2 ulU/ml) and elevated (TSH > 4.2ulU/ml). Free thyroxine (FT4) was also grouped into normal (FT4 12–23 pmol/L) and low (FT4 < 12 pmol/L). Elevated TSH along with normal Free T4 level was classified as primary hypothyroidism, while elevated TSH level with normal Free T4 level was classified as subclinical hypothyroidism. Growth delay was determined by annual height velocity less than the expected for age as follows: 2–4 years : < 7 cm/year, 4–6 years : < 6 cm/year, 6 years-till pubertal onset : < 4.5 cm/ year [19]. In addition, the height of each study participant was standardized by calculating its relative Z score, and consequently, patients with z score values below − 2 were considered to have short stature.

Ethical approval

Data collection for this research commenced after granting ethical approval from Dubai Scientific Research Ethics Committee at Dubai Health Authority. The reference number for the approval letter is DSREC-06/2019-10.

Results

This study analyzed data of a total of 105 children (n = 39) and adolescents (n = 66) with β thalassemia. The mean age was 5.38 years (sd = 2.145) for children and 15.22 years (sd = 2.361) for adolescents. Females composed 51.3% (n = 20) of children and 53.0% (n = 35) of the adolescents. Of all study participants, 45.5% (n = 46) were UAE nationals, 24.8% (n = 25) were Arabs, 29.7% (n = 30) were non-Arabs, and 3.8% (n = 4) had other nationalities. For adolescent girls, the mean age of menarche was 13.5 years (sd = 1.503). Among all study participants, 22.6% (n = 14) had normal height velocity whereas 37.1% (n = 23) had reduced height velocity in one year and 40.3% (n = 25) had reduced height velocity in two consecutive years. In other words, 77.4% (n = 48) of all children and adolescents had reduced height velocity at least in one year (Table 1). Among all study participants, short stature (Z score < -2) was reported in three children, two boys and a girl.

Table 1 Demographic and physical characteristics of children (2–9 years) and adolescents (10–18 years) with beta thalassemia
Full size table

The proportion of patients with pretransfusion hemoglobin below 9 gm/dl was 10.8% (n = 4) among children and 10.6% (n = 7) among adolescents. The median ferritin level in children was 2213 (IQR: 1636–3181) and 2521 (IQR: 1621–3789) in adolescents. Although none of the study participants had diabetes mellitus, 26.1% (n = 12 out of 46) had pre-diabetes. Elevated TSH was observed in 14.7% (n = 5) of the children and 8.1% (n = 5) of the adolescents while abnormal FT4 (FT4 < 12 pmol/L) was reported in only one child and one adolescent (Table 2). Children with elevated TSH levels had a median ferritin value of 2468 (IQR: 1596–3148) and were all within the normal range of FT4 (between 12 and 23). Blood transfusion was done by all the children and adolescents, with the majority performing blood transfusion once every three weeks. Regarding the chelation drug therapy, the majority of patients were on a single chelation drug (95.3%, n = 100) while only 3.8% (n = 4) used two drugs simultaneously. These four patients were adolescents while all children were on a single chelator. Of the total 105 study participants, one patient did not use chelation therapy as she had undergone bone marrow transplant. 14.3% (n = 15) used DFO, 2.9% (n = 3) used DFP, 78.1 (n = 82) were on DFX, 1.9% (n = 2) were on DFO and DFX, and 1.9% (n = 2) were on DFP and DFX. Among children, the drugs used for chelation therapy were Deferoxamine (DFO) (28.2%) and Deferasirox (DFX) (66.7%) while among the adolescents, DFO was used by 6.1%, Deferiprone (DFP) by 3.0%, and DFX by 84.8% (Table 2).

Table 2 Clinical characteristics of children (2–9 years) and adolescents (10–18 years) with beta thalassemia
Full size table

Ferritin level were done every 3 months and ferritin level was studied in association with demographic, physical and clinical parameters. Ferritin level significantly differed by the use of DFO chelation drug where ferritin level was 3034 among the DFO drug users compared to 2183 among the non-users (U = 1045, p-value = 0.004) (Table 3).

Table 3 Comparing Ferritin level by other parameters
Full size table

The proportion of children and adolescents showing reduced height velocity was significantly higher in females compared to the males (90.6% versus 63.3%, respectively, Chi-square = 6.597, p-value = 0.010). Split analysis by age group has revealed that reduced height velocity was significantly higher in females than males of the adolescent’s group (90.5% compared to 62.5%, respectively, Chi-square = 4.194, p-value = 0.040), and not in the children group. Reduced height velocity was not associated with any of the other factors (Table 4).

Table 4 Comparing height velocity measured in two consecutive years by other parameters
Full size table

The prevalence of pre-diabetes did not differ significantly by age group, gender, nationality, BMI, or type of chelation drug (Table 5). Prediabetic patients (n = 12) had a median Ferritin level of 2466 (IQR: 2091–3539). The prevalence of hypothyroidism among children and adolescents, was significantly higher among non-Arabs (26.9%) compared to UAE nationals (4.5%) and Arabs (4.2%; Chi-square = 10.028, p-value = 0.007). Among all study participants, the prevalence of subclinical hypothyroidism was 9.5% (n = 10), and none had primary hypothyroidism.

Table 5 Prevalence of pre-diabetes by type of drug chelation & other parameters
Full size table

Discussion

Endocrine complications is common among patients with BTM, of which short stature seems the most prevalent (49%) [20]. Males were found to have higher prevalence than females in prior studies, however, our study found females to have statistically significant higher percentage of reduced height velocity in females. There are several factors contributing to such a high rate including iron overload particularly in the liver iron concentration of > 15 mg Fe/g dry weight [21]. Furthermore, pituitary iron overload has been postulated as an etiology for growth failure with malfunction of somatotrophs, in addition to defective hepatic growth hormones receptors [22, 23]. Studies have reported high prevalence of growth hormone deficiency [20]. Menarche occurred at a later age ( 13.5 years) in girls with BTM in comparison with the mean age for menarche in the general population in UAE which is 12.6 years [24]. This delay in menarche could partly explain why females are more affected than males in terms of reduced growth velocity.

Due to the small number of patients with Hb less than 9 g/dL, it is hard to conclude the association between low Hb and reduced height velocity among children and adolescents with BTM in our study. However, other studies have reported significant difference in pretransfusion hemoglobin and ferritin level between children with normal height and those with stunted growth [25].

Glucose dysregulation has been well documented in patients with BTM due to different etiologies including iron deposition in the beta cells in the pancreas which occur typically after the first decade of life, zinc deficiency, and hepatitis C [26,27,28]. More than a quarter (26.5%) of adolescents treated at our centre were found to be in a prediabetes state. This is comparable to other published data from different regions [29, 30]. Although relative insulin deficiency is the most common cause for the pre-diabetic state, obesity and its associated insulin resistance is known to accelerate the onset of diabetes. Therefore, it is important that clinicians advise healthy lifestyle including healthy diet and regular physical activity to delay the onset of diabetes.

Thyroid gland seem to be affected in patients with BTM and the impact of hypothyroidism shows mostly after the age of 10. There is a wide range of prevalence of hypothyroidism ranging 13–60% in different parts of the world [9, 31,32,33,34,35,36,37]. We found 9.1% prevalence of subclinical hypothyroidism and none with primary hypothyroidism suggesting that this might occur after adolescent years.

BMT is the preferred choice of treatment when matched donor is available [38,39,40,41]. Although many endocrinological complications seem to occur despite bone marrow transplant, gonadal insufficiency is found to be significantly lower among children who undergone transplant early in life [42].

Conclusion

Despite the effective treatment protocols in the UAE, growth delay remains the main concern for this group of patients. effective treatment is key to further reducing endocrinopathies. Although the sample size is limited, we postulate that the low percentage of endocrinopathies among children with BTM treated at Dubai thalassemia center and the low level of pretransfusion anemia reflect the effective transfusion and chelation at the center.

Data availability

The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.

References

  1. Origa R. β-Thalassemia. Genet Med. 2017;19(6):609–19.

    Article  CAS  PubMed  Google Scholar 

  2. Thein SL. Molecular basis of β thalassemia and potential therapeutic targets. Blood Cells Mol Dis. 2018;70:54–65.

    Article  CAS  PubMed  Google Scholar 

  3. Taher AT, Saliba AN. Iron overload in Thalassemia: different organs at different rates. Hematol Am Soc Hematol Educ Program. 2017;2017(1):265–71.

    Article  Google Scholar 

  4. Fibach E, Dana M. Oxidative stress in β-Thalassemia. Mol Diagn Ther. 2019;23(2):245–61.

    Article  CAS  PubMed  Google Scholar 

  5. Taksande A, Prabhu S, Venkatesh S. Cardiovascular aspect of Beta-thalassaemia. Cardiovasc Hematol Agents Med Chem. 2012;10(1):25–30.

    Article  CAS  PubMed  Google Scholar 

  6. Kushwaha SS, Fallon JT, Fuster V. Restrictive cardiomyopathy. N Engl J Med. 1997;336(4):267–76.

    Article  CAS  PubMed  Google Scholar 

  7. Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR. Thalassemia Clinical Research Network. Complications of beta-thalassemia major in North America. Blood. 2004;104(1):34–9.

    Article  CAS  PubMed  Google Scholar 

  8. Noetzli LJ, Panigrahy A, Mittelman SD, Hyderi A, Dongelyan A, Coates TD, et al. Pituitary iron and volume predict hypogonadism in transfusional iron overload. Am J Hematol. 2012;87(2):167–71.

    Article  CAS  PubMed  Google Scholar 

  9. De Sanctis V, Soliman AT, Canatan D, Yassin MA, Daar S, Elsedfy H, et al. Thyroid disorders in homozygous β-Thalassemia: current knowledge, emerging issues and open problems. Mediterr J Hematol Infect Dis. 2019;11(1):e2019029.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Tangngam H, Mahachoklertwattana P, Poomthavorn P, Chuansumrit A, Sirachainan N, Chailurkit L et al. or,. Under-recognized Hypoparathyroidism in Thalassemia. J Clin Res Pediatr Endocrinol. 2018;10(4):324–30.

  11. Merkel PA, Simonson DC, Amiel SA, Plewe G, Sherwin RS, Pearson HA, et al. Insulin resistance and hyperinsulinemia in patients with Thalassemia major treated by hypertransfusion. N Engl J Med. 1988;318(13):809–14.

    Article  CAS  PubMed  Google Scholar 

  12. Suvarna J, Ingle H, Deshmukh CT. Insulin resistance and beta cell function in chronically transfused patients of Thalassemia major. Indian Pediatr. 2006;43(5):393–400.

    PubMed  Google Scholar 

  13. Shalitin S, Carmi D, Weintrob N, Phillip M, Miskin H, Kornreich L, et al. Serum ferritin level as a predictor of impaired growth and puberty in Thalassemia major patients. Eur J Haematol. 2005;74(2):93–100.

    Article  CAS  PubMed  Google Scholar 

  14. American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44(Suppl 1):15–33.

    Article  Google Scholar 

  15. Petersmann A, Müller-Wieland D, Müller UA, Landgraf R, Nauck M, Freckmann G, et al. Definition, classification and diagnosis of diabetes Mellitus. Exp Clin Endocrinol Diabetes. 2019;127(S 1):1–7.

    Google Scholar 

  16. Guidelines for the Management of Transfusion Dependent Thalassaemia, 3rd Edition. (2014) – English [Internet]. TIF. [cited 2023 Mar 21]. Available from: https://thalassaemia.org.cy/download/guidelines-for-the-management-of-transfusion-dependent-thalassaemia-3rd-edition-2014-english/.

  17. Thalassemia-Guidelines_LR. pdf [Internet]. [cited 2023 Mar 21]. Available from: http://www.thalassemia.ca/wp-content/uploads/Thalassemia-Guidelines_LR.pdf.

  18. UKTS [Internet]. [cited 2023 Mar 21]. UKTS. Available from: https://ukts.org/.

  19. Lifshitz F, editor. Pediatric Endocrinology, two volume set. 5th ed. Boca Raton: CRC; 2014. p. 1352.

    Google Scholar 

  20. Arab-Zozani M, Kheyrandish S, Rastgar A, Miri-Moghaddam E. A systematic review and Meta-analysis of stature growth complications in β-thalassemia major patients. Ann Glob Health. 2021;87(1):48.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Yassin MA, Soliman AT, de Sanctis V, Abdula MA, Riaz LM, Ghori FF, et al. Statural growth and prevalence of endocrinopathies in relation to liver iron content (LIC) in adult patients with beta thalassemia major (BTM) and sickle cell disease (SCD). Acta Bio Med Atenei Parm. 2018;89(Suppl 2):33–40.

    CAS  Google Scholar 

  22. Pintor C, Cella SG, Manso P, Corda R, Dessĭ C, Locatelli V, et al. Impaired growth hormone (GH) response to GH-releasing hormone in Thalassemia major. J Clin Endocrinol Metab. 1986;62(2):263–7.

    Article  CAS  PubMed  Google Scholar 

  23. Al-Elq AH, Al-Saeed HH. Endocrinopathies in patients with thalassemias. Saudi Med J. 2004;25(10):1347–51.

    PubMed  Google Scholar 

  24. Badrinath P, Ghazal-Aswad S, Parfitt D, Osman N. Cultural and ethnic barriers in conducting research. Factors influencing menarche in the United Arab Emirates. Saudi Med J. 2004;25(11):1626–30.

    PubMed  Google Scholar 

  25. Moiz B, Habib A, Sawani S, Raheem A, Hasan B, Gangwani M. Anthropometric measurements in children having transfusion-dependent beta thalassemia. Hematol Amst Neth. 2018;23(4):248–52.

    Google Scholar 

  26. Nimkarn N, Songdej D, Dumrongwongsiri O, Sirachainan N, Chuansumrit A, Thalassemia Study Group. Age as a major factor associated with zinc and copper deficiencies in pediatric thalassemia. J Trace Elem Med Biol Organ Soc Min Trace Elem GMS. 2021;68:126817.

    Article  CAS  Google Scholar 

  27. De Sanctis V, Soliman A, Tzoulis P, Daar S, Fiscina B, Kattamis C. The pancreatic changes affecting glucose homeostasis in transfusion dependent β- thalassemia (TDT): a short review. Acta Bio-Medica Atenei Parm. 2021;92(3):e2021232.

    Google Scholar 

  28. Fung EB, Gildengorin G, Talwar S, Hagar L, Lal A. Zinc Status affects glucose homeostasis and insulin secretion in patients with thalassemia. Nutrients. 2015;7(6):4296–307.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. De Sanctis V, Daar S, Soliman AT, Tzoulis P, Karimi M, Di Maio S, et al. Screening for glucose dysregulation in β-thalassemia major (β-TM): an update of current evidences and personal experience. Acta Bio Med Atenei Parm. 2022;93(1):e2022158.

    Google Scholar 

  30. Liang Y, Bajoria R, Jiang Y, Su H, Pan H, Xia N, et al. Prevalence of diabetes mellitus in Chinese children with Thalassaemia major. Trop Med Int Health TM IH. 2017;22(6):716–24.

    Article  CAS  PubMed  Google Scholar 

  31. Ashraf TS, De Sanctis V, Yassin M, Wagdy M, Soliman N. Chronic anemia and thyroid function. Acta Bio Med Atenei Parm. 2017;88(1):119–27.

    Google Scholar 

  32. Landau H, Matoth I, Landau-Cordova Z, Goldfarb A, Rachmilewitz EA, Glaser B. Cross-sectional and longitudinal study of the pituitary-thyroid axis in patients with Thalassaemia major. Clin Endocrinol (Oxf). 1993;38(1):55–61.

    Article  CAS  PubMed  Google Scholar 

  33. Upadya SH, Rukmini MS, Sundararajan S, Baliga BS, Kamath N. Thyroid function in chronically Transfused Children with Beta Thalassemia Major: a cross-sectional hospital based study. Int J Pediatr. 2018;2018:9071213.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Najafipour F, Aliasgarzadeh A, Aghamohamadzadeh N, Bahrami A, Mobasri M, Niafar M, et al. A cross-sectional study of metabolic and endocrine complications in beta-thalassemia major. Ann Saudi Med. 2008;28(5):361–6.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Zervas A, Katopodi A, Protonotariou A, Livadas S, Karagiorga M, Politis C, et al. Assessment of thyroid function in two hundred patients with beta-thalassemia major. Thyroid off J Am Thyroid Assoc. 2002;12(2):151–4.

    Article  Google Scholar 

  36. Malik SA, Syed S, Ahmed N. Frequency of hypothyroidism in patients of beta-thalassaemia. JPMA J Pak Med Assoc. 2010;60(1):17–20.

    PubMed  Google Scholar 

  37. Kurtoglu AU, Kurtoglu E, Temizkan AK. Effect of iron overload on endocrinopathies in patients with beta-thalassaemia major and intermedia. Endokrynol Pol. 2012;63(4):260–3.

    CAS  PubMed  Google Scholar 

  38. Lawson SE, Roberts IAG, Amrolia P, Dokal I, Szydlo R, Darbyshire PJ. Bone marrow transplantation for β-thalassaemia major: the UK experience in two paediatric centres. Br J Haematol. 2003;120(2):289–95.

    Article  PubMed  Google Scholar 

  39. Di Bartolomeo P, Santarone S, Di Bartolomeo E, Olioso P, Bavaro P, Papalinetti G, et al. Long-term results of survival in patients with Thalassemia major treated with bone marrow transplantation. Am J Hematol. 2008;83(7):528–30.

    Article  PubMed  Google Scholar 

  40. Sabloff M, Chandy M, Wang Z, Logan BR, Ghavamzadeh A, Li CK, et al. HLA-matched sibling bone marrow transplantation for β-thalassemia major. Blood. 2011;117(5):1745–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Caocci G, Orofino MG, Vacca A, Piroddi A, Piras E, Addari MC, et al. Long-term survival of beta thalassemia major patients treated with hematopoietic stem cell transplantation compared with survival with conventional treatment. Am J Hematol. 2017;92(12):1303–10.

    Article  CAS  PubMed  Google Scholar 

  42. Aldemir-Kocabaş B, Tezcan-Karasu G, Bircan I, Bircan O, Aktaş-Samur A, Yeşilipek MA. Evaluating the patients with Thalassemia major for long-term endocrinological complications after bone marrow transplantation. Pediatr Hematol Oncol. 2014;31(7):616–23.

    Article  PubMed  Google Scholar 

Download references

Funding

The study was funded by seed grant from University of Sharjah-United Arab Emirates.

Author information

Authors and Affiliations

  1. Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates

    Rabah Almahmoud

  2. Department of Family & Community Medicine and Behavioral Sciences, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates

    Amal Hussein

  3. Dubai Thalassemia Centre, Dubai Health Authority, Dubai, United Arab Emirates

    Fatheya Al Khaja, Ahmed Farrag Soliman & Hany Dewedar

  4. Department of Basic Sciences, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates

    Zainab Al Shareef

  5. Department of Pediatrics, Christian Medical College, Vellore, India

    Sarah Mathai

Authors
  1. Rabah Almahmoud
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amal Hussein
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fatheya Al Khaja
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ahmed Farrag Soliman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hany Dewedar
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zainab Al Shareef
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Sarah Mathai
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

RA and SM conceived the research idea, participated in data analysis and writing the manuscript, AH did the statistical analysis and writing the manuscript. FA, HD, AFS, and ZA participated in the writing the manuscript.

Corresponding author

Correspondence to Rabah Almahmoud.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest related to the study.

Ethics approval and consent to participate

The ethical approval was obtained from Dubai Scientific Research Ethics Committee at Dubai health authority (Reference DSREC-06/2019_10). Written informed consent to participate in the study was obtained from the parents and/or caregiver for children less than ten years of age. Written informed consent to participate was obtained from the patients as well as the parents and/or caregiver for patients 10 year and older.

Consent for publication

Not applicable.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Almahmoud, R., Hussein, A., Khaja, F.A. et al. Growth and endocrinopathies among children with β-Thalassemia major treated at Dubai Thalassemia centre. BMC Pediatr 24, 244 (2024). https://doi.org/10.1186/s12887-024-04670-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12887-024-04670-w

Keywords

BMC Pediatrics

ISSN: 1471-2431

Contact us